AC Immune (ACIU) Interest & Investment Income (2015 - 2026)
AC Immune (ACIU) reported Interest & Investment Income of $291157.1 for Q1 2026, down 61.9% year-over-year from $764116.1 in Q1 2025, and down 34.08% on a QoQ basis from $441662.9 in Q4 2025.
AC Immune (ACIU) has 12 years of Interest & Investment Income data on file, last reported at $291157.1 in Q1 2026.
- Quarterly Interest & Investment Income fell 61.9% year-over-year to $291157.1 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.7 million (down 52.62% YoY) and the FY2025 annual result came in at $2.2 million, down 38.34% from the prior year.
- Interest & Investment Income declined to $291157.1 in Q1 2026 per ACIU's latest filing, from $441662.9 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $1.1 million in Q3 2024 and bottomed at -$435044.8 in Q2 2022.
- The 5-year median for Interest & Investment Income is $441662.9 (2025), against an average of $443191.5.
- The widest annual swing landed in 2022, when Interest & Investment Income plunged 99.76%; it then soared 2732.86% in 2023.
- Tracing ACIU's Interest & Investment Income over 5 years: stood at $842873.8 in 2022, then sank by 61.08% to $328060.2 in 2023, then soared by 209.34% to $1.0 million in 2024, then slumped by 56.48% to $441662.9 in 2025, then slumped by 34.08% to $291157.1 in 2026.
- Per Business Quant, the three latest ACIU Interest & Investment Income figures stand at $291157.1 (Q1 2026), $441662.9 (Q4 2025), and $457540.1 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 7.90 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 114.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 305,000.00 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 26.60 Mn |
| 10 | AC Immune | 325.88 Mn | 211.53 Mn | - | 291,157.07 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 291,157.07 |
| Dec 31, 2025 | 441,662.94 |
| Sep 30, 2025 | 457,540.08 |
| Jun 30, 2025 | 553,213.72 |
| Mar 31, 2025 | 764,116.12 |
| Dec 31, 2024 | 1.01 Mn |
| Sep 30, 2024 | 1.08 Mn |
| Jun 30, 2024 | 817,181.39 |
| Mar 31, 2024 | -2.37 Mn |
| Dec 31, 2023 | 328,060.15 |
| Sep 30, 2023 | 322,663.48 |
| Jun 30, 2023 | 288,053.47 |
| Mar 31, 2023 | -63,788.59 |
| Dec 31, 2022 | 842,873.79 |
| Sep 30, 2022 | 11,390.02 |
| Jun 30, 2022 | -435,044.77 |
| Mar 31, 2022 | -193,822.70 |
| Dec 31, 2021 | 12.41 Mn |
| Sep 30, 2021 | 4.82 Mn |
| Sep 30, 2020 | 79,304.68 |
| Jun 30, 2020 | 17,642.80 |
| Mar 31, 2020 | 60,996.95 |
| Dec 31, 2019 | 67,695.70 |
| Sep 30, 2019 | 74,091.45 |
| Jun 30, 2019 | 74,798.09 |
| Mar 31, 2019 | 89,361.56 |
| Dec 31, 2018 | 124,599.51 |
| Sep 30, 2018 | -1.34 Mn |
| Jun 30, 2018 | 2,031.91 |
| Mar 31, 2018 | 1,054.41 |
| Mar 31, 2017 | 12,947.53 |
| Dec 31, 2016 | 5.20 Mn |
| Sep 30, 2016 | 35,879.22 |
| Mar 31, 2016 | 1,006.92 |
| Dec 31, 2015 | 1.57 Mn |
| Sep 30, 2015 | 7,265.21 |